Back to Browse Journals » International Journal of Nanomedicine » Volume 9 » Issue 1
Enhanced and selective delivery of enzyme therapy to 9L-glioma tumor via magnetic targeting of PEG-modified, ß-glucosidase- conjugated iron oxide nanoparticles
Authors Zhou J, Zhang J, Gao W
Received 21 December 2013
Accepted for publication 17 February 2014
Published 10 June 2014 Volume 2014:9(1) Pages 2905—2917
DOI https://doi.org/10.2147/IJN.S59556
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Jie Zhou,1,* Jian Zhang,2,* Wenxi Gao1
1Department of Urology, Hubei Hospital of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, People’s Republic of China; 2Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA
*These authors contributed equally to this work
Abstract: The stability of enzyme-conjugated magnetic iron oxide nanoparticles in plasma is of great importance for in vivo delivery of the conjugated enzyme. In this study, ß-glucosidase was conjugated on aminated magnetic iron oxide nanoparticles using the glutaraldehyde method (ß-Glu-MNP), and further PEGylated via N-hydroxysuccinimide chemistry. The PEG-modified, ß-glucosidase-immobilized magnetic iron oxide nanoparticles (PEG-ß-Glu-MNPs) were characterized by hydrodynamic diameter distribution, zeta potential, Fourier transform infrared spectroscopy, transmission electron microscopy, and a superconducting quantum interference device. The results showed that the multidomain structure and magnetization properties of these nanoparticles were conserved well throughout the synthesis steps, with an expected diameter increase and zeta potential shifts. The Michaelis constant was calculated to evaluate the activity of conjugated ß-glucosidase on the magnetic iron oxide nanoparticles, indicating 73.0% and 65.4% of enzyme activity remaining for ß-Glu-MNP and PEG-ß-Glu-MNP, respectively. Both magnetophoretic mobility analysis and pharmacokinetics showed improved in vitro/in vivo stability of PEG-ß-Glu-MNP compared with ß-Glu-MNP. In vivo magnetic targeting of PEG-ß-Glu-MNP was confirmed by magnetic resonance imaging and electron spin resonance analysis in a mouse model of subcutaneous 9L-glioma. Satisfactory accumulation of PEG-ß-Glu-MNP in tumor tissue was successfully achieved, with an iron content of 627±45 nmol Fe/g tissue and ß-glucosidase activity of 32.2±8.0 mU/g tissue.
Keywords: ß-glucosidase, enzyme/prodrug therapy, magnetic nanoparticles, magnetic targeting, 9L-glioma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Readers of this article also read:
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus
Jeong HR, An SSA
Clinical Interventions in Aging 2015, 10:1873-1879
Published Date: 19 November 2015
Hematuria following Botox treatment for upper limb spasticity: a case report
Lo TC, Yeung ST, Lee S, Chang EY
Journal of Pain Research 2015, 8:619-622
Published Date: 14 September 2015
Magnetic microparticle-based multimer detection system for the detection of prion oligomers in sheep
Lim K, Kim SY, Lee B, Segarra C, Kang S, Ju YR, Schmerr MJ, Coste J, Kim SY, Yokoyama T, An SSA
International Journal of Nanomedicine 2015, 10:241-250
Published Date: 9 September 2015
Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders
Cai Y, An SSA, Kim SY
Clinical Interventions in Aging 2015, 10:1163-1172
Published Date: 14 July 2015
Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries
Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M
Patient Preference and Adherence 2014, 8:1713-1720
Published Date: 12 December 2014
Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A
Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S
Neuropsychiatric Disease and Treatment 2014, 10:865-867
Published Date: 16 May 2014
A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
Lentz SR, Tandra A, Gut RZ, Cooper DL
Journal of Blood Medicine 2014, 5:1-3
Published Date: 13 January 2014
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
International Journal of Nanomedicine 2010, 5:581-591
Published Date: 6 August 2010
Crystallization after intravitreal ganciclovir injection
Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant
Clinical Ophthalmology 2010, 4:709-711
Published Date: 14 July 2010
Characterization of complexation of poly (N-isopropylacrylamide-co-2-(dimethylamino) ethyl methacrylate) thermoresponsive cationic nanogels with salmon sperm DNA
Jim Moselhy, Tasnim Vira, Fei-Fei Liu, et al
International Journal of Nanomedicine 2009, 4:153-164
Published Date: 24 August 2009
